Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CCNH | P51946 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10090581 | 0.86 | ALK (0.36) | BRD4PDPK1CCND1TRPV1 | |
| SCHEMBL6445454 | 0.85 | KMT2A (0.36) | PDPK1BTK | |
| SCHEMBL1727256 | 0.85 | TRPV1 (0.38) | PDE4APDE4BPDE4CPDE4DCCND1 | |
| SCHEMBL6446484 | 0.82 | ALK (0.34) | PDPK1TRPV1 | |
| SCHEMBL6444232 | 0.80 | NPC1 (0.34) | — | |
| SCHEMBL2692666 | 0.79 | CYP3A4 (0.45) | BRD4CREBBPPDPK1TDP2 | |
| SCHEMBL2695946 | 0.78 | CA1 (0.40) | PDPK1 | |
| SCHEMBL2691334 | 0.75 | CYP3A4 (0.50) | BRD4CREBBPBRD9PDPK1TDP2 | |
| SCHEMBL3077934 | 0.73 | GPR84 (0.38) | TRPV1 | |
| SCHEMBL1727595 | 0.73 | NPC1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168792-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-01 | — | — | US | claimed |
| US-20100226879-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ABBOT SARAH C | 2010-09-09 | — | — | US | claimed |
| US-8168792-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100226879-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ABBOT SARAH C | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226879-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, IFNAR1, RRM2B | PDE4A 3032/4885PDE4B 2540/4885PDE4C 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.